Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline access to the popular treatment.

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.

A new study is out that compares the effectiveness of two popular weight loss drugs, Wegovy and Zepbound. The study, which was conducted by Eli Lilly, the maker of Zepbound, found that weight loss with Zepbound was significantly more than Wegovy.

New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new efforts to market the drug as shortages ease. Recent months have brought new questions about whether the sky-high expectations for Zepbound’s sales—which have sent Lilly’s share price up more than 230% over the past three years—may be overly optimistic.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.